Endometrial cancer after Tamoxifen treatment of breast cancer. Results of a retrospective cohort study

European Journal of Gynaecological Oncology

Volumn 20, Issue 1, 1999, Pages 20-25

  Vrščaj, Marjetka Uršič ^a   Bebar, S ^a   Djurisic, A ^a   Fras, P A ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Breast cancer; Endometrial cancer; Tamoxifen

Indexed keywords

TAMOXIFEN CITRATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CURETTAGE; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYPERPLASIA; HYSTERECTOMY; MAJOR CLINICAL STUDY; POLYP; RETROSPECTIVE STUDY; RISK FACTOR; SLOVENIA; STATISTICAL ANALYSIS; UTERUS BLEEDING;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; SLOVENIA; TAMOXIFEN;

EID: 0344197594     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Craig J.,: "Tamoxifen treatment for breast cancer: concept to cold standard". Oncology, 1997, Vol. 11, No. 2 (suppl. No. 1), 7.
2. Jordan V. C.: "Antiestrogenic and antitumor properties of tamoxifen in laboratory animals". Cancer Treat. Rep., 1976, 60, 1409.
3. Jordan V. C.: "Antitumor activity of the antiestrogen ICI 46,474 (tamoxifen) in the dimethyl-benzanhthracene (DMBA)-induced rat mammary carcinoma model". J. Steroid. Biochem., 1974, 5, 354.
4. Jaiyesimi I. A., Buzdar A. U., Decker D. A. et al.: "Use of tamoxifen for breast cancer: twenty-eight years later". J. Clin. Oncol., 1995, 13, 513.
5. Robinson E., Kimmick G. G., Muss H. B.: "Tamoxifen in postmenopausal women: a safety perspective". Drugs & Aging, 1996, 8, 329.
6. Ingle J. N., Krook J. E., Gren S. J. et al.: "Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer". J. Clin. Oncol., 1986, 4, 178.
7. Cutuli B., Lacroze M., Dilhuydy J. M. et al.: "Male breast cancer: results of the treatment and the prognostic factors in 397 cases". Eur. J. Cancer, 1995, 31A, 1960.
8. Borgen P., Wong G., Vlamis V. et al;: "Current management of male breast cancer: a review of 104 cases". Ann. Surg., 1992, 215, 451.
9. Nolvadex Adjuvant Trial Organization (NATO): "Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer". Lancet, 1985, 1, 836.
10. Breast Cancer Trials Committee, Scottish Cancer Trials Office: "Adjuvant tamoxifen in the management of operable breast cancer: the Scotish trial". Lancet, 1987, 2, 171.
11. Swedish Breast Cancer Co-Operative Group: "Randomized trial of 2 versus 5 years of adjuvant therapy in node positive breast cancer". J. Natl. Cancer Instit., 1996, 88, 1543.
12. Early Breast Cancer Trialists* Collaborative Group: "Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: part 1". Lancet, 1992, 339, 1.
13. Jordan V. C., Phelps E., Lindgren J. U.: "Effects of antiestrogens on the bone in castrated and intact female rats". Breast Cancer Res. Treat., 1987, 10, 31.
14. Love R. R., Mazess R. B., Barden H. S. et al.: "Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer". N. Engl. J. Med., 1992, 326, 852.
15. Bilimoria M. M., Assikis V. J., Jordan V. C.: "Should tamoxifen therapy be stopped at 5 years?". Cancer J. Sci. Am., 1996, 2, 140.
16. Rutqvist L. E., Mattson A.: "Cardiac and thromboembolic morbidity among prostmenopausal women with early-stage cancer in a randomized trial of adjuvant tamoxifen". J. Natl. Cancer Inst., 1993, 85, 1398.
17. McDonald C. C., Stewart H. J.: "Fetal myocardial infarction in the Scottish tamoxifen trial". Br. Med. J., 1991, 303, 435.
18. McDonald C. C., Alexander F. E., Whyte B. W. et al.: "Cardiac and vasclar morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial". Br. Med. J., 1995, 311, 977.
19. Anteby E., Yagel S., Zacut D., Palti Z., Hochner-Celnikier D.: "False sonographic appearence of endometrial neoplasia in postmenopausal women treated with tamoxifen". Lancet, 1992, 340, 433.
20. Cohen I., Rosen D. J., Shapira J. et al.: "Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer". Br. J. Obstet. Gynecol., 1993, 100, 567.
21. Nuovo M. A., Nuovo G., McCaffrey R. M., Levine R. U., Baron B., Winkler B.: "Endometrial polyps in postmenopausal patients receiving tamoxifen". Int. J. Gynecol. Pathol., 1989, 8, 125.
22. Pons J. Y., Abeille J. P., Legros R.: "Effets uterins paradoux du tamoxifene". Gynecologia, 1983, 4, 573.
23. Leo L., Tessarolo M., Febo G., Farina C., Nuzzo L., Arduino S. et al.: "Tamoxifen and endometrial cancer: new data for an old problem. Review". Eur. J. Gynecol. Oncol., 1997, 429.
24. Reichman B. S.: "Tamoxifen's impact on the management of breast cancer: patient perspectives". Oncology, 1997, Vol. 11, No. 2 (suppl. No. 1), 55.
25. Incidenca raka v Sloveniji. Register raka za Slovenijo, 1994.
26. Robert N. J.: "Clinical efficacy of tamoxifen". Oncology, 1997, Vol. 11, No. 2 (suppl. No. 1), 15.
27. Morgan R. W.: "Risk of endometrial cancer after tamoxifen treatment". Oncolology, 1997, Vol. 11, No. 2 (suppl. No. 1), 25.
28. Killackey M. A., Hakes T. B., Pierce V. K.: "Endometrial adenocarcinorna in breast cancer patients receiving antiestrogens". Cancer Treat. Rep., 1985, 69, 237.
29. Fisher B., Constantino J. P., Redmond C. K., Fisher E. R., Wicherham L., Cronin W. M.: "Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National adjuvant breast and bowel project (BSAPB-14)". J. Natl. Cancer Inst., 1994, 86, 527.
30. Fornander T., Hellstrom A. C., Moberger B.: "Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer". J. Natl. Cancer Inst., 1993, 85, 1850.
31. Andersson M., Storm H. H., Mouridsen H. R.: "Carcinogenetic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer". Acta Oncol., 1992, 31, 259.
32. Ryden S., Ferno M., Moller T. et al.: "Long-term effects of adjuvant tamoxifen and/or radiotherapy: the South Sweden breast cancer trial". Acta Oncol., 1992, 31, 271.
33. Castiglione M., Gelber R. D., Goldhirsch A.: "Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality". J. Clin. Oncol., 1990, 8, 519.
34. Champion P. E., Nabholtz J. M., Jenkins G. et al.: "Is tamoxifen increasing the risk of uterine malignancy in women treated for breast cancer?". Breast Cancer Res. Treat., 1991, 19, 195.
35. Ribeiro G., Swidel R.: "The Christie Hospital adjuvant tamoxifen trial". Natl. Cancer Inst. Monogr:, 1992, 11, 121.
36. Stewart H. J.: "The Scottish trial of adjuvant tamoxifen in node-negative breast cancer". Natl. Cancer Inst. Monogr., 1992, 11, 117.
37. Boccardo F., Amorso D., Rubagotti A. et al.: "Prolonged tamoxifen treatment of early breast cancer: the experience of the Italian cooperative group for chemohormonal therapy of early breast cancer, in long-term tamoxifen treatment for breast cancer". Madison, University of Wisconsin press, 1994, 159.
38. Cummings F. J., Gray R., Toreny D. C. et al.: "Adjuvant tamoxifen versus placebo in elderly women with node-negative breast cancer: long-term follow-up and causes of death". J. Clin. Oncol., 1993, 11, 29.
39. Powles T. J., Jones A. L., Ashley S. E. et al.: "The Royal Marsden Hospital pilot tamoxifen chemoprevention trial". Breast Cancer Res. Treat., 1994, 31, 73.
40. Anonymous: "Tamoxifen and the uterus and endometrium". Lancet, 1989, 31, 73.
41. Lahti E., Blanco G., Kauppila A. et al.: "Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen". Obstet. Gynecol., 1993, 81, 660.
42. Cook L. S., Weiss N. S., Schwartz S. M. et al.: "Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancer". J. Natl. Cancer Inst., 1995, 67, 1359.
43. Robinson D. C., Bloss J. D., Schiano M. A.: "A retrospective study of tamoxifen and endometrial cancer in breast cancer patients". Gynecol. Oncol., 1995, 59, 186.
44. Sasco A. J., Chaplain G., Amoros E. et al.: "Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy". Epidemiology, 1996, 7, 9.
45. Hoover R., Eversol R., Fraumeni J. F., Myers M. H.: "Cancer of the uterine corpus after hormonal treatment for breast cancer". Lancet, 1975, 1, 885.
46. Fornander T., Rutquist L. E., Ceder M. B. et al.: "Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancer". Lancet, 1989, 1, 117.
47. Hardell L.: "Pelvic irradiation and tamoxifen as risk factor for carcinoma of corpus uteri". Lancet, 1988, 2, 1432.
48. Assikis V. J., Neven P., Jordan V. C. et al.: "A realistic clinical perspective of tamoxifen and endometrial carcinogenesis". Eur. J. Cancer Part. A, 1996, 32A, 1464.
49. Ziel H. K.: "Estrogen's role in endometrial cancer". Obstet. Gynecol., 1982, 60, 509.
50. Morgan R.: "Risk of endometrial cancer after tamoxifen treatment". Oncology, 1997, Vol. 11, No. 2 (suppl. No. 1), 25.
51. Magriples U., Naftolin F., Schwartz P. E., CarCangiu M. L.: "High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients". J. Clin. Oncol., 1993, 11, 485.
52. Silva E. G., Torros L. S., Fallen-Mitchell M.: "Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen". Int. J. Gynecol. Pathol., 1994, 13, 248.
53. Malfetano J.: "Tamoxifen - associated endometrial carcinoma in postmenopausal breast cancer patients". Gynecol. Oncol., 1990, 39, 82.
54. vanLeeuwen F. E., Benrradt J., Coebergh J. W., Kiemency L., Gimbrene C. H., Otter R. et al.: "Risk of endometrial cancer after tamoxifen treatment of breast cancer". Lancet, 1994, 343, 448.
55. Barakat R. R., Wong G., Cuutin J. P., Viamis V., Hoskins W. J.: "Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features". Gynecol. Oncol. (In press).
56. Barakat R. R.: "Benign and hyperplastic endometrial changes associated with tamoxifen use". Oncology, 1997, Vol. 11, No. 2 (suppl. No. 1), 35.
57. De Muylder X., Neven P., De Somer M., Van Belle Y., Vanderick G., De Muylder E.: "Endometrial lesions in patients undergoing tamoxifen therapy". Int. J. Gynecol. Obstet., 1991, 36, 127.
58. Kedar R. P., Bourne T. H., Powles T. J., Collins W. P., Ashley S. E., Cosgrove D. O., Campbell S.: "Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial". Lancet, 1994, 343, 1318.
59. Corely D., Rowe J., Curtis M., Hagan M., Noumoff J. A., Livols V. A.: "Postmenopausal bleeding from unusual endometrial polyp in women on chronic tamoxifen therapy". Obstet. Gynecol., 1992, 79, 111.
60. Swenberg J. A.: "Clinical relevance of laboratory and animal data on tamoxifen". Oncology; 1997, Vol. 11, No. 2 (suppl. No. 1), 39.
61. Stearns V., Gelmann E. P.: "Does tamoxifen cause cancer in humans?". J. Clin. Oncol., 1998, Vol. 16, No. 2 (February), 779.
62. Cohen I., Rosen D. J., Shapira J., Cordoba M., Gilbou S., Altaras M. M. et al.: "Endometrial changes with tamoxifen: comparison between tamoxifen-treated and non-treated asymptomatic, postmenopausal breast cancer patients". Gynecol. Oncol., 1994, 52, 185.